Schrodinger Inc. released a corporate presentation covering its fourth-quarter and full-year 2025 financial performance and business updates. The company reported full-year 2025 total revenue of $255.9 million, including software revenue of $199.5 million and drug discovery revenue of $56.4 million, with cash and equivalents of $402.3 million as of December 31, 2025. The presentation also introduced software and drug discovery key performance indicators, including total annual contract value of $198.5 million in 2025, and outlined progress on shifting software deployments toward hosted contracts, with hosted revenue representing 23 percent of 2025 software revenue. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Schrodinger Inc. published the original content used to generate this news brief on February 25, 2026, and is solely responsible for the information contained therein.